article
11 April 2022 | By Dr Andrew Bradbury (Specifica), Dr Bryan Jones (Eli Lilly & Company), Dr Erica Ollmann Saphire (La Jolla Institute for Immunology), Dr Gary Cohen (University of Pennsylvania), Dr Molly Gibson (Generate Biomedicines)
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.